BioSpace News Archive

Longboard Pharmaceuticals, Inc. today announced Steven W. Spector, J.D., has joined the company as its General Counsel.

CorMedix Inc. today announced that it will report its financial results for the third quarter ended September 30, 2021, after the market close on Tuesday, November 9, 2021, and will host a corporate update conference call at 4:30pm Eastern Time.

Landos Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for LABP-104, a novel, oral, systemically delivered LANCL2 agonist, for the treatment of rheumatoid arthritis (RA).

GeneVentiv Therapeutics, a pre-clinical gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GENV-HEM for the treatment of Hemophilia A or B with or without inhibitors.

Surmodics, Inc. today announced that it will host a live webcast of its fourth quarter fiscal 2021 conference call on Wednesday, November 10, at 7:30 a.m. CT (8:30 a.m. ET).

Perimeter Medical Imaging AI, Inc. today announced approval of its Investigational Device Exemption (“IDE”) application by the U.S. Food and Drug Administration (“FDA”) to conduct a multi-center, randomized, double-arm study to evaluate the FDA breakthrough-device-designated Perimeter B-Series OCT imaging system

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it has completed the filing of the New Animal Drug Application (NADA) to request the U.S. Food and Drug Administration’s conditional approval to market Canalevia

NeoSpine is now offering spinal cord stimulation (SCS) procedure(s) for the treatment of painful diabetic neuropathy (PDN).

Klarisana Psychedelic Therapies is pleased to announce the publication of its second case study analyzing the use of ketamine for the treatment of major depressive disorder.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.